Here are the 424B prospectus supplements from PARKERVISION INC (PRKR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRKR filings page.
ParkerVision, Inc. completed a registered direct offering of 4,761,905 shares of common stock to board member Lewis H. Titterton, Jr. for $1,000,000, priced at $0.21 per share, equal to the last reported OTCQB sale price on November 14, 2025. The company received the full amount with no underwriting or placement fees.
Shares outstanding increase from 121,549,398 to 126,311,303, and the transaction causes immediate dilution, with pro forma net tangible book value rising from approximately $(0.42) to $(0.40) per share. Management plans to use the net proceeds for working capital and other general corporate purposes, including litigation fees and expenses, as ParkerVision continues to focus on enforcing its RF patent portfolio.
ParkerVision, Inc. has filed a prospectus supplement that allows selling shareholders to resell up to 9,387,500 shares of common stock, primarily from previously issued shares and shares underlying convertible notes and options. The company will not receive proceeds from these resales, and would receive only up to $42,620 if certain options are exercised for cash.
Attached to the supplement is ParkerVision’s latest quarterly report, showing a net loss of about $7.4 million for the nine months ended September 30, 2025 and no revenue. Cash and cash equivalents were roughly $0.9 million against current liabilities of about $2.9 million, including $1.6 million of convertible debt due within a year, and large long-term contingent payment obligations. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern without new licensing wins, successful litigation outcomes or additional financing.